AJANTPHARM vs VENUSREM: Stock Comparison
AJANTA PHARMA is the larger company by market capitalisation. AJANTA PHARMA shows a higher ROE, a higher dividend yield and a higher ROCE, while VENUSREM shows a lower P/E, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AJANTPHARM leads 7; VENUSREM leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AJANTPHARM | VENUSREM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AJANTPHARM | VENUSREM |
|---|---|---|
| Live Price | ₹3,435.6 | ₹1,796.7 |
| Day Change | -3.76% | 0.03% |
| Volume | 83,212 | 1.17 L |
| 52-Week High | ₹3,796 | ₹1,880 |
| 52-Week Low | ₹2,380.2 | ₹432.1 |
| Distance from 52W High | -9.49% | -4.43% |
Valuation
| Metric | AJANTPHARM | VENUSREM |
|---|---|---|
| Market Cap | ₹42,93,092.23 L Cr | ₹2,233 Cr |
| P/E Ratio | 37.92x | 19.22x |
| P/B Ratio | 9.51x | 3.36x |
| EPS | ₹87.38 | ₹19.1 |
| Book Value | ₹362.35 | ₹496.56 |
| Dividend Yield | 1.79% | 0.56% |
Growth
| Metric | AJANTPHARM | VENUSREM |
|---|---|---|
| Revenue Growth (TTM YoY) | 21.5% | 33% |
| EPS Growth (TTM YoY) | 18.6% | 126.4% |
| Qtr Sales Growth | 9.22% | -0.03% |
| Qtr Profit Growth | 5.94% | 11.14% |
Profitability & Leverage
| Metric | AJANTPHARM | VENUSREM |
|---|---|---|
| ROE | 23.33% | 15.49% |
| ROCE | 23.05% | 16.2% |
| Net Margin | 19.38% | 13.35% |
| Operating Margin | 25.56% | 17.56% |
| Debt to Equity | 0.05x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AJANTPHARM | VENUSREM |
|---|---|---|
| Promoter Holding | 63.48%▼ 2.77 pp | 41.76% |
| FII Holding | 7.68%▼ 0.58 pp | 2.92%▲ 0.12 pp |
| DII Holding | 21.8%▲ 3.43 pp | 0.89%▼ 0.31 pp |
| Public Holding | 7.03%▼ 0.09 pp | 54.43%▲ 0.19 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AJANTA PHARMA and VENUSREM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.